Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
about
H5N1 vaccines in humansH5 influenza, a global update.Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics.Development of live attenuated influenza vaccines against pandemic influenza strains.Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetSimplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine.A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.Considerations for the rapid deployment of vaccines against H7N9 influenza.Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.Emulsion-based adjuvants for influenza vaccines.Using plant cells as influenza vaccine substrates.Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.Vaccines for an influenza pandemic: scientific and political challenges.Refining the approach to vaccines against influenza A viruses with pandemic potential.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicPreservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.Pandemic influenza vaccines - the challenges.New technologies for influenza vaccines.Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variantSafety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variantInfluenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.FluBlok, a recombinant hemagglutinin influenza vaccine.Statistical estimation & inference of cell counts from ELISPOT limiting dilution assaysSafety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.Morphological and reproductive characterization in hyacinth bean, Lablab purpureus (L.) sweet germplasm with clinically proven nutraceutical and pharmaceutical traits for use as a medicinal food.The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Editorial Commentary: Is Prepandemic Vaccination a Wise Investment?Intranasal live influenza vaccine priming elicits localized B cell responses in mediastinal lymph nodes.Vaccines against epidemic and pandemic influenzaAvian Influenza A Virus Pandemic Preparedness and Vaccine DevelopmentCD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential
P2860
Q27000896-08179519-E0C7-425D-96FF-26573E2F58A9Q30151309-CD16CB31-DE10-48FB-8AB9-2B9FC5398A60Q30202032-C6AEF64B-44FA-4B82-B903-71F0AF424FF7Q30209998-9666574D-C5D0-49D6-BC59-0521C1F2BE54Q30223058-E7912231-AF24-44D8-B8E9-6E1C31858287Q30227194-7210AF42-886D-4767-A807-F47921307E63Q30358537-E120DAC2-ED7A-4ABC-9A5D-3DA9000C09A6Q30359896-AAB0423A-02C7-4D81-97E2-5DF8138ACE40Q30362811-02DE275D-B566-4A82-9E56-AC61DE846F28Q30364635-CD1A6066-DF02-4B21-AD23-5AC0EC7DD7C5Q30368474-991C2BCC-7397-4D0D-B60F-65FCE942B2F1Q30372087-8CC005CF-08CE-4EB0-A106-1CBE3B3895FDQ30372360-551BF7AB-B409-4ECB-BDC7-DA2B08D475EDQ30375985-3EDA6E8A-94A9-4DDD-8ACB-032754BD7DEAQ30375988-4D1201CD-084D-450E-8357-B9C3959575D4Q30376757-90FBF0C9-3907-489A-8F98-15AADE7D2AC0Q30376971-BA5FAEDC-B9D4-4D54-8C0B-F49040B64B33Q30381595-91636417-4015-4833-B7F5-92AA0EF1EA02Q30382097-61F30BBD-FC5B-4FF8-B304-F3BE9592C5ECQ30382809-E8AEB810-09B1-4179-8404-9C8083CBB126Q30383451-3069259E-F6D5-48A7-8B2A-131A7CED143BQ30386212-AC9D7A0A-45E2-489F-A3CE-6C8913295CD9Q30402307-3B46C197-764B-4C1F-BB58-824C09A06C6BQ30407657-B21577CA-A4AF-4F91-B297-789D1FDE2CE3Q30408091-DC2BF9BB-83F9-423E-BC4E-F21F2BB631DDQ30411859-9F77ADDC-D335-438B-80F0-EC32EB13C292Q30420397-245DA48C-8EDE-404D-8CA7-8EA165C074B1Q33624415-2528D763-B357-48EC-A2BE-5A56ABD2F4B8Q33808135-3E6F5772-0303-4CEA-81D2-3C0DDC495D10Q34407701-3EE9197A-85A5-451F-87AB-105C3ED89AE9Q36251189-DD7DA09B-0D06-4334-B8CA-76E8046DE604Q37243043-5B9C2007-46EC-4EF2-85FF-3B52BFBF2C99Q37316012-721F7096-E024-4442-9F93-BFB661FEC8FEQ37995663-ACA13982-BECF-46AA-B99F-2B4E34F7948FQ38388047-04DD4FA8-7A3F-4192-8072-5FFEDD0916BAQ45058836-A59B740E-B3A4-46AF-8297-B1C33348697BQ50146914-81A1C30D-8379-4CCB-A8F9-D285F09C722EQ56550815-59A78EC4-CBAE-4E47-8D25-A7B3E6488D65Q56561344-566CFD2D-1F85-4975-A48D-17779DC20435Q57094380-BD28FB17-F362-465E-AD37-DF867C2B2442
P2860
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Immune responses of healthy su ...... ing with an antigenic variant.
@ast
Immune responses of healthy su ...... ing with an antigenic variant.
@en
type
label
Immune responses of healthy su ...... ing with an antigenic variant.
@ast
Immune responses of healthy su ...... ing with an antigenic variant.
@en
prefLabel
Immune responses of healthy su ...... ing with an antigenic variant.
@ast
Immune responses of healthy su ...... ing with an antigenic variant.
@en
P2093
P356
P1476
Immune responses of healthy su ...... ing with an antigenic variant.
@en
P2093
Carrie Nolan
Diana L Noah
Heather Hill
John J Treanor
Mark Wolff
Nega Ali Goji
Thomas Rowe
Tracy B Williams
P304
P356
10.1086/590916
P407
P577
2008-09-01T00:00:00Z